Interview with Dr. Yoichi Kato | Japanese Immunotherapy Authority Visits Hong Kong
Spotlight on Japan’s Leading Immunotherapy Authority
Hong Kong, May 2 – Dr. Yoichi Kato, a renowned figure in Japanese immunotherapy, arrived in Hong Kong from Yokohama for a four-day visit.
Significant Efficacy in Late-Stage Cases
During the interview, Dr. Kato highlighted a real-life case involving a terminal patient whose cancer cells had spread across the abdominal cavity, umbilical region, liver (with a tumor larger than 10 cm), and lungs. The patient also experienced intestinal obstruction in the abdominal cavity. After a thorough evaluation, Dr. Kato devised a three-month immunocellular therapy regimen that markedly curtailed further tumor growth and spread. Following an additional three months of treatment, the tumor burden stabilized and then declined. In fact, the 10-cm liver lesion completely disappeared, while abdominal nodules continued to shrink—underscoring the promising potential of immunocellular therapy in tackling complex, late-stage cancers.
Industry Outreach: Insurance Companies and Private Hospitals
Dr. Kato was also invited by CHUBB Life Insurance to present clinical cases and emerging trends in immunocellular therapy to a group of insurance brokers, with the aim of exploring broader insurance coverage to support patients in need. Later, he visited St. Teresa’s Hospital (France Hospital) to tour the facility and engage in in-depth discussions with local healthcare practitioners. These industry interactions sought to identify new ways Hong Kong’s medical community could integrate and benefit from immunocellular approaches.
Science Park Visit: A Close Look at Hong Kong’s R&D Capabilities
On his final stop, Dr. Kato toured Hong Kong’s Science Park, where local research teams showcased the region’s latest developments in immunocellular therapy. Discussions centered on cross-border medical technology transfer and clinical applications, with both parties envisioning a globalized future for immunotherapy through international cooperation.
Japan’s Immunocellular Therapy: A Global Leader
Japan’s immunocellular therapy surged in the 1990s and early 2000s, gaining official recognition from the Ministry of Health, Labour and Welfare in 2006. Dr. Kato has been a driving force in this pioneering field since the 1990s, when he served as a project director at Japan’s National Cancer Center. He has to date treated over 2,000 cases—one of the highest volumes and success rates in the entire country.
Moving forward, Dr. Kato aims to bring Japan’s cutting-edge immunotherapy to a wider global audience, sharing knowledge and expertise so that more patients can benefit from safer and more precise treatment options. He expressed deep appreciation for Hong Kong’s medical infrastructure and research capabilities during this visit and believes the groundwork has been laid for robust collaboration—accelerating the adoption of immunocellular therapies on an even larger international scale.
